Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future?

M Hingorani, WP Colley, S Dixit… - The British journal of …, 2012 - academic.oup.com
The prognosis of patients with glioblastoma (GBM) remains poor, and the use of
hyperfractionation or dose escalation beyond 60 Gy has not conferred any survival benefit …

Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future?

M Hingorani, WP Colley, S Dixit… - The British Journal of …, 2012 - europepmc.org
The prognosis of patients with glioblastoma (GBM) remains poor, and the use of
hyperfractionation or dose escalation beyond 60 Gy has not conferred any survival benefit …

[HTML][HTML] Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future?

M Hingorani, WP Colley, S Dixit… - The British Journal of …, 2012 - ncbi.nlm.nih.gov
The prognosis of patients with glioblastoma (GBM) remains poor, and the use of
hyperfractionation or dose escalation beyond 60 Gy has not conferred any survival benefit …

Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future?

M Hingorani, WP Colley, S Dixit… - The British journal of …, 2012 - pubmed.ncbi.nlm.nih.gov
The prognosis of patients with glioblastoma (GBM) remains poor, and the use of
hyperfractionation or dose escalation beyond 60 Gy has not conferred any survival benefit …

[引用][C] Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future?

M Hingorani, WP Colley, S Dixit… - The British Journal of …, 2012 - cir.nii.ac.jp
Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the
future? | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future?

M Hingorani, WP Colley, S Dixit… - The British Journal of …, 2012 - europepmc.org
The prognosis of patients with glioblastoma (GBM) remains poor, and the use of
hyperfractionation or dose escalation beyond 60 Gy has not conferred any survival benefit …